Background. Sympathetic overactivity is frequently observed following renal transplantation (RTx), and post-transplant hypertension is a major contributing factor to graft failure and cardiovascular morbidity. This process is perpetuated by preservation of sympathetic afferent activity from the native non-functional kidneys, in the absence of efferent feedback to the renal transplant, which would otherwise modulate neurohumoral activity. We investigated the feasibility and efficacy of renal sympathetic denervation (RDN) in renal transplant recipients. Methods. Patients (n = 18) with post-transplant hypertension were randomized 1:1 to receive RDN or medical treatment alone. The primary efficacy end point was change in office systolic blood pressure (SBP) and mean 24-h ambulatory blood pressure monitoring (ABPM) at 6 months. Safety end points were changes in renal function or renovascular complications. Results. After 6 months, patients in the RDN group had a significant reduction in office SBP of 23.3 ± 14.5 mmHg (P = 0.001 for change difference between the groups). In ABPM, nocturnal blood pressure was reduced in the RDN group by −10.38 ± 12.8 mmHg (P = 0.06), whereas no change was measured during the day. In the RDN group, significantly more patients converted from non-dippers to dippers (P = 0.035). There were no adverse safety events in either group.
sympathetic nerve activity arising from the native kidneys [1] . In addition, immunosuppressive drugs, e.g. calcineurin inhibitors, which are commonly used in organ transplantation recipients, provide for vasoconstriction and might enhance that mechanism. There is growing evidence that calcineurin inhibitors mediate activation of renal afferents [8] and sympathetic nervous activation [9] . Also, other specific factors such as graft function and renal artery stenosis of the graft artery influence BP [8] .
Catheter-based radiofrequency denervation of the renal arteries has emerged as a promising treatment for resistant hypertension complementary to medical treatment [10] . Conflicting BP-lowering effects of this approach have been reported. Initial unblinded randomized trials demonstrated a reduction in BP, as measured at an ambulatory office visit [11] , with a persistent effect after years [12, 13] . But a lack of 24-h ambulatory BP monitoring (ABPM) and a lack of standardized antihypertensive treatment complicate the interpretation of these results. Resent trails addressed these limitations with discordant conclusions [14, 15] . Differences in methodology might have contributed to that disparity. Currently the first and only shamcontrolled SYMPLICITY HTN-3 trial with largely negative results raises important questions about the effectiveness and application of renal denervation [16] . However, post hoc analyses reveal several potential confounding factors concerning patient selection and the ablation technique that may partially explain the unexpected BP responses in that trial [17] .
Commonly the aetiology of arterial hypertension is multifactorial, including not only sympathetic overactivity, but also metabolic, heritable, lifestyle and dietary factors. Therefore it is unlikely that renal sympathetic denervation (RDN) is equally effective in every single patient. Since the concept of RDN is directed at reducing sympathetic overactivity, it is conceivable that patients after RTx, in whom this factor is most prevalent, might derive particular benefit from RDN.
We hypothesized that RDN of the native kidneys in renal transplant recipients might reduce sympathetic overactivity and systemic BP. In this setting, RDN would allow for a selective examination of the effects of sympathetic afferent activity arising from the non-functional native kidneys. We therefore investigated the feasibility and efficacy of this approach in patients with poorly controlled post-transplant hypertension.
M AT E R I A L S A N D M E T H O D S
Patients and study design Renal transplant recipients 18-85 years old at least 6 months after transplantation with a diagnosis of persistent hypertension were eligible for inclusion. All patients provided signed informed consent. Patients were eligible for inclusion if they had an uncontrolled office-based systolic BP (SBP) >140 mmHg despite treatment with at least three antihypertensive drugs including one diuretic, with no changes in medication for a minimum of 2 weeks before enrolment. Patients were excluded if they had an eGFR ≤30 mL/min/1.73 m 2 (based on the Modification of Diet in Renal Disease criteria). The study was an investigator-initiated, prospective, single-centre trial and was approved by the local ethics committee and the Federal Office for Radiation Protection. The trial was registered at https://www. clinicaltrials.gov (NCT01899456). No outside funding was used for the study.
Patients were recruited from referrals to the outpatient clinic and consecutively randomized 1:1 in the order that they were enrolled to receive either RDN of the native kidneys in addition to medical treatment or to medical treatment alone. Randomization was after the screening period at the time of the outpatient visit with sealed envelopes containing a computer-generated sequence. Randomization was stratified by study centre. Data analysers were not masked regarding treatment group assignment and blindly evaluated by independent physicians.
Renal denervation procedure
Patients were treated between July 2013 and March 2014. Renal angiograms were performed via femoral access of the side contralateral to the transplanted kidney. The diameter of renal arteries was not restricted. The ablation catheter (Flex; Medtronic, Inc., Mountain View, CA, USA) was introduced into each native renal artery using a 6-Fr guiding catheter. Six ablations at 8 W for a total time of 2 min each were performed in both renal arteries. In cases where ablation was stopped due to catheter tip temperatures achieving pre-programmed limits, ablation was continued to a total time of 2 min/site. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored and delivery of radiofrequency energy was regulated by a pre-determined algorithm. Pain during the radiofrequency delivery was managed with intravenous analgesics and sedatives. Heparin was given at a dosage of 50-70 IU/kg.
Measurements and follow-up
Office BP, calculated as the average of three measurements at an office visit while the patient was seated, was assessed before RDN, at 30 days and at 6 months after the procedure. Twenty-four-hour ABPM (oscillometric Spacelabs 90207-32; Spacelabs Healthcare, Issaquah, WA, USA) was performed before RDN and every 6 months thereafter. Readings were taken every 30 min during the day and every 60 min at night. Only ambulatory BP assessments that met the European Society of Cardiology and European Society of Hypertension guidelines (with >70% of daytime and night-time readings) were eligible for inclusion in the analysis [18] . Mean SBPs and diastolic BPs (DBPs) were calculated as daytime and night-time period averages for every patient. The proportion of patients who were extreme dippers (decline >20% in night to day BP), dippers (10-20% decline in night to day BP), non-dippers (<10% decline in BP at night) and reverse dippers (night BP > day BP) were calculated at baseline and after 6 months.
Patients underwent non-invasive 30-min recordings of electrocardiogram and continuous BP at baseline and after 6 months using a finger photoplethysmographic device (Finapres; TNO-TPD Biomedical Instrumentation, Amsterdam, The Netherland). To assess cardiac baroreflex behaviour, RR intervals and SBP values were calculated by phase-rectified signal averaging (PRSA) [19, 20] .
Patients were followed clinically at 1, 3 and 6 months with assessment of adverse events and medication prescription and compliance and measurements of office-based BP, serum creatinine concentration, glomerular filtration rate (GFR) and urine albumin: creatinine ratio. Changes in antihypertensive medication were not allowed during the 6-month follow-up period unless clinically required. Medication adherence was confirmed by a patient logbook in which daily BP measurements or medication changes were documented. Control of this documentation was performed 30, 90 and 180 days after the follow-up.
End points
The primary efficacy end point was the change in office systolic blood pressure (SBP) and mean 24-h ambulatory SBP at 6 months. The secondary efficacy end point included effects on sympathetic activity assessed by baroreflex at months. In addition to 24-h ABPM, daytime and night-time ambulatory BP differences from baseline to 6 months, as well as differences in the change between the two groups, were assessed. Spontaneous baroreflex sensitivity (BRS PRSA ) was assessed at baseline and at 6 months. The primary safety end point was the change in renal function measured by changes in GFR, creatinine and albuminuria at 30 days, or renovascular complications assessed by duplexsonography after RDN prior to discharge. All BP readings were measured by assessors who were unaware of the treatment allocation.
Statistical analysis
The aim of the study was to test the superiority of renal denervation compared with medical treatment alone in renal transplant recipients with persistent hypertension. The null hypothesis was that there would be no difference between the groups. This trial was planned to be powered for the primary efficacy end point at 6 months. Patients were planned to be analysed in the groups to which they were assigned. With a planned sample size of 20 patients per group, we calculated that the study would have at least 80% power to show benefit of renal denervation over control intervention with respect to the primary end point, assuming a ≥ 18 mmHg difference between groups and a 20 mmHg SD of the change in office SBP from baseline to 6 months. Sample size calculation was performed using GraphdPad 6.0 software (GraphPad Software, La Jolla, CA, USA). However, during the enrolment period, results of the sham-controlled SYMPLICITY HTN-3 trial were presented, indicating that the general benefit of RDN might have been overestimated in unblinded studies. In light of these results, we decided to stop our unblinded trial and to perform a premature analysis.
Continuous data are reported as mean (SD); categorical data are reported as number ( percentage). Differences between groups regarding continuous variables were tested with Student's two-sample t-test unless otherwise specified. We compared categorical variables with Fisher's exact test. For within-group paired data, a paired t-test was used unless otherwise specified. A two-sided α level of 0.05 was used for all superiority testing. All statistical analyses were done with SPSS version 20.0 (IBM, Armonk, NY, USA).
R E S U LT S
Patient study flow is shown in Figure 1 . From 9 July 2013 to 7 March 2014, 18 patients were enrolled and randomly allocated either to RDN and medical therapy or medical therapy alone. The baseline characteristics are shown in Table 1 and were well matched between the groups. Patients in both groups were receiving similar numbers and types of antihypertensive drugs. Diuretics were used in >89% of patients.
On average, treated patients received a total of 12.6 ± 6.2 ablation treatments for a total of 2 min each. Repetitive ablations were 4.5 in mean in cases where the procedure was stopped. The mean diameter of renal arteries was 3.92 ± 1.36 mm ( Table 2) .
Of 18 patients who were randomly allocated to intervention or control groups, 17 had data available for the primary end point analysis. One patient in the RDN group was lost to followup. There were no changes in antihypertensive medication at follow-up. In one patient from the denervation group, preprocedure BRS data were not available due to a technical problem.
The primary efficacy end point was the mean change in office BP from baseline to 6 months after randomization. In the denervation group, office-based BP was significantly reduced by 23/9 mmHg (SD 14.5/8.7) (P = 0.003 for SBP and P = 0.02 for DBP). In contrast, in the control group, office BP did not change (+1/− 1±13/10.1 mmHg; P = 0.77 for SBP and P = 0.77 for DBP; Figure 2 ). Therefore, a 24/11 mmHg reduction in office-based BP between both groups was noted (P < 0.001 for SBP and P = 0.09 for DBP) at 6-month follow-up ( Figure 2) .
No change in the co-primary end point of overall mean 24-h ABPM was noted in denervation group or in the control group (−2.88/−1.38 ± 11.1/6.0 mmHg, P = 0.49/P = 0.53 versus −5.0/ −4.67 ± 11.1/9.6 mmHg, P = 0.21/P = 0.18). Also, no change in systolic or diastolic 24-h ABPM was noted during the day in the denervation group [+1.5/−0.25 ± 13.4/7.7 mmHg (P = 0.76/P = 0.93) versus −5.18/−5.1 ± 12.6/9.7 mmHg (P = 0.25/P = 0.15) in the control group].
In contrast, night-time systolic ABPM changed by −10.38 ± 12.8 mmHg (P = 0.06) in the denervation group, compared with 1.97 ± 12.2 mmHg (P = 0.64) in the control group. Correspondingly, night-time diastolic 24-h ABPM declined in the denervation group by 8.3 ± 12.17 mmHg (P = 0.09) (from 76.1 ± 9.3 to 67.8 ± 10.2 mmHg), compared with 0.9 ± 9.9 mmHg (P = 0.8) (from 78.2 ± 13.0 mmHg to 77.3 ± 10.1) in the control group. The resulting difference in nocturnal ABPM between groups was 12.35 mmHg (P = 0.18) for SBP and 7.4 mmHg (P = 0.19) for DBP (Figure 3 ). In the denervation group, three patients converted from non-dippers to dippers, in contrast to none in the control group (P = 0.035). Overall, significantly more patients in the denervation group (four of eight) improved their nocturnal DBP >10% compared with the control group (one of nine) (Supplementary data, Figure S1 ). The results of analysis of the safety end points are given in Table 3 . There was no difference in the safety end point parameters between the groups. Two patients developed a pseudo-aneurysm at the femoral vascular access site, both of which were managed conservatively by pressure application or thrombin injection without any sequelae. There was no increase in serum creatinine at 48 h (P = 0.8) or 6 months (P = 0.62) after ablation. The GFR did not differ between the groups at 30 days or 6 months. Albuminuria was reduced at 6 months in the ablation group by 94.6 ± 153.7 g/dL compared with 32.5 ± 62.9 g/dL (P = 0.31) for the control group.
D I S C U S S I O N
This randomized, non-blinded trial demonstrates the feasibility and safety of renal artery denervation in the selected population of renal transplant recipients. It shows a benefit of renal artery denervation on the primary end point of office-based BP but failed to show a reduction in 24-h ambulatory SBP. Night-time ABPM was improved in the renal denervation group, whereas no difference between the denervation and control groups was seen in daytime ABPM.
Consistent with previous non-blinded studies of renal denervation in patients with persistent hypertension, our study also shows a significant reduction in office-based BP in renal transplant recipients. This reduction is significantly greater than in the control group with drug treatment alone. However, concordant with the sham-controlled SYMPLICITY HTN-3 trial, no reduction in 24-h ABPM after 6 months was evident in our study. Baseline ABPM levels of the entire cohort are lower than office baseline BPs, which was an inclusion criterium. This is consistent with other hypertension or renal sympathetic denervation trials. Moreover, differences between office BP and 24-h ABPM in renal transplant recipients seem to be greater compared with other hypertensive patients [21] . However, analysis after excluding patients with mean systolic 24-h ABPM ≤130 mmHg at baseline confirmed the results (data not shown). Together with the small sample size, this low baseline value in 24-h ABPM might partly explain the lack of BP reduction in 24-h ABPM in that trial. Interestingly, a considerable reduction in nocturnal ABPM was noted, although no differences were noted during the day. The same effect tended to be seen in the kidney-healthy patients of the SYMPLICITY HTN-3 trial. However, the reduction 
O R I G I N A L A R T I C L E
I S A R -d e n e r v e appears to be more apparent in the collective of renal transplant patients.
Correspondingly, significantly more patients in the ablation group converted from reverse dippers or non-dippers at baseline to dippers after 6 months. This conversion was previously observed after RDN in patients with chronic kidney disease (CKD). [22] . The reason for these effects could be an increased sympathetic overactivity in CKD patients and renal transplant recipients without nephrectomy. This overactivity has been demonstrated in previous physiological studies [1, 23] . A similar detrimental influence of the sympathetic nervous system on BP and renal function in renal transplant patients seems plausible.
Patients with chronic renal insufficiency and those post-RTx often suffer from high blood pressure, which is well known to be associated with increased cardiovascular morbidity and mortality [3] . Moreover, 25-50% of these patients are non-compliant with medical therapy, with intermittent omission of some or all drugs. Poor medication adherence increases acute rejection rates, graft loss and death [24] . Medication non-adherence increases with the increasing number of drugs and transplant duration [25] . Immunosuppression with calcineurin inhibitors promotes vasoconstriction and might enhance activation of renal afferents [8] and the sympathetic nervous system [9] . Therefore successful catheter ablation therapy might be particularly important in this patient group.
Previous studies on renal denervation excluded patients with ESRD or post-RTx, despite the fact that these patients could particularly benefit from this treatment modality. The rationale for excluding these patients in earlier trials was partly due to a potential risk of deterioration in renal function and partly due to altered anatomy of the renal arteries in these patients due to degenerative processes. This means that the vessel calibre of the native renal arteries is often less than what is normally felt to be the requisite for catheter ablation. Accordingly, one objective of our study was to investigate the feasibility and safety of renal denervation in renal transplant patients. In fact, quantitative analysis of the renal arteries of enrolled patients confirmed a calibre less than the threshold normally accepted for RDN therapy in F I G U R E 2 : Primary efficacy end point, paired changes in office-based BP after 30, 90 and 180 days. ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; SBP, systolic blood pressure. *P < 0.001, # P = 0.09 for reduction in office-based blood pressure between the both groups.
F I G U R E 3 : Primary efficacy end point, paired changes in 24-h ABPM overall, at daytime and at night-time after 6 months. ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; SBP, systolic blood pressure. *P < 0.06, # P = 0.09 for reduction in blood pressure within the group. almost 85% of patients. One consequence of this was that more often energy delivery through the catheter had to be discontinued (due to increasing catheter temperature) prior to reaching the desired duration of ablation. This was overcome by performing multiple shorter ablations while remaining within recommended catheter operational parameters. We continued ablation for a total time of 2 min. Whether this approach achieves an equal depth of radiofrequency ablation with comparable modulation of the sympathetic nervous system remains unclear. However, only 4.5 of 12.6 were repetitive ablations in case of abored procedures. A correlation between the abored procedure rate and response rate, however, was not evident. Moreover, despite the discontinuation rate, a comparable reduction in BP as in the SYMPLICITY HTN-3 trial could be achieved. In future studies, this limitation could be overcome through the use of a cooled ablation catheter or ultrasound ablation catheter. With a mean of 12.6 ablation attempts, treated patients received a comparable number of ablation treatments as treated patients in the HTN-1 and HTN-2 trials. The latest post hoc analysis from SYMPLICITY HTN-3 indicates that with a higher number (12-15 ablations) of ablation attempts, significantly greater reductions in SBP can be achieved [17] .
Importantly, no adverse safety events were observed in our study, and safety end points in relation to renal function did not occur in any patient. In contrast, in the denervation group, a slight reduction in proteinuria after 6 months was noted. Similar effects on albuminuria were demonstrated in previous studies with larger numbers of patients [26] . This is of particular interest since lower proteinuria levels are associated with prolonged graft survival [27] .
It has previously been demonstrated that restoration of renal function through kidney transplantation does not reduce muscle sympathetic nerve activity, which is accompanied by persistent hypertension, as long as the native kidneys are still in situ [1, 28] . Only RTx combined with bilateral nephrectomy can achieve this state of normalized sympathetic nerve activity [1, 28] . The secondary end point of this investigation was to assess the effects on sympathetic nerve activity through a functional nephrectomy by catheter ablation of the renal nerves supplying the native kidneys. In the absence of efferent sympathetic nerves to the functional transplanted kidney, renal denervation in renal transplant recipients presented an almost selective modulation of central sympathetic nerve activity. Information about autonomic nervous activity is accessible by analysing the cardiac BRS. Impaired cardiac BRS is a well-known phenomenon in hypertensive patients that has been linked to sympathetic overactivity [29, 30] .
Recently it has been shown that impaired BRS, which is indicative of increased sympathetic tone, predicts response to RDN in patients with resistant hypertension [31] . Due to the small sample size, we cannot make any confident statement about whether this holds true for hypertensive renal transplant recipients. However, we observed an improvement of BRS after 6 months in the RDN group but not in the control group. This corroborates the Values are mean (SD), change from baseline to 6 months and difference in change in measured concentrations of eGFR, serum creatinine and albuminuria for renal denervation and control groups. eGFR was calculated on the basis of Modification of Diet in Renal Disease Study criteria.
pathophysiological concept that RDN of native non-functional kidneys reduces sympathetic tone in this patient population.
Study limitations
An important limitation of our study is that the patient recruitment was stopped early due to the availability of data from a large multicentre trial with sham control, which showed no benefit of RDN in non-RTx patients with resistant hypertension. We initially planned to enrol 40 patients. In light of the availability of the data from October 2014, we made the decision to stop enrolment and analyse the data after inclusion of 18 patients. As a result, we acknowledge that the trial is underpowered for the comparison between the groups in relation to the primary end point. In fact, the results of the SYMPLICITY HTN-3 study underpin the importance of a sham-control arm in studies aimed at testing the efficacy of renal denervation. We therefore felt that it would have been inappropriate to continue our study as planned in light of these results. However, given the promising results of our prematurely terminated study, a follow-up study incorporating a sham-control design might be justified.
CO N C L U S I O N
Our study demonstrates the feasibility and safety of RDN in renal transplant recipients with persistent hypertension. RDN significantly reduced office but not 24-h ambulatory BP in comparison with medical treatment alone, though this must be interpreted in light of a lack of sham control. These findings should be confirmed in larger studies ideally with sham controls.
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